A case of sudden rapid neurological deterioration in an HIV positive 27 year old female

Patient Presentation

An HIV positive 27 year old female on antiretroviral therapy (ART) presented to her HIV clinic with a two week history of progressively worsening twitching and clumsiness in her right hand. The twitching had become continuous making it difficult for her to use her hand. Her family also reported witnessing three seizures over the last two weeks with loss of consciousness on each occasion.

History

Three months previously she was admitted to hospital for measles complicated by pneumonitis. It is unknown if she had ever been vaccinated against measles as no records or anecdotal evidence of childhood vaccinations were available. At time of admission she was tested HIV positive. The CD4 receptor on helper T cells binds to HLA class II and the interaction causes CD4 helper T cell activation. CD4+ T cells coordinate the immune response by releasing cytokines and signalling to other cells via cell-cell contact that enables others immune cells to perform their specialised functions (such as B cells). The number of CD4 cells in a sample of blood is an indicator of the health of the immune system.
system. A normal CD4 count ranges from 500 to 1500. HIV infects and kills CD4 cells, leading to a weakened immune system and lower CD4 counts. CD4 cell count was 67 cells/ul.

She recovered and was discharged four weeks later. At this time she was initiated on ART, co-trimoxazole and multivitamins. Her follow-up visits had been uneventful, reports showing that she had been doing well.

**Past Medical History**

- Measles complicated by pneumonitis, requiring four week hospital admission
- HIV positive, on treatment.
- No previous history of epilepsy or other neurological disorders.
- No other medical history of significance.

**Past Surgical History**

- No previous surgical history

**Vaccination History**

- Unknown

**Family History**

- Nothing of significance

**Allergies**

- Nil known

**Medication**

- Tenofovir, 3TC and EFV
- Co-trimoxazole
- Multivitamins

**Travel History**

- Never traveled away from home city

**Social History**

- Non smoker
- No alcohol
No illegal substance use

**Differential Diagnosis**

- Acute encephalitis
- CMV encephalitis
- Subacute measles encephalitis
- Acute demyelinating encephalomyelitis (ADEM) post measles
- Progressive multifocal leukoencephalopathy (PML)
- CNS neoplasm
- Tuberculoma
- Arteriovenous malformation
- Head trauma

**Examination**

**Examination on Admission**

**Appearance**

- Thin but not ill looking
- Awake, alert and co-operative
- Not encephalopathic
- GCS 15/15

**Vitals**

- Temperature: 37.0°C, afebrile
- Blood pressure: 115/76
- Heart rate: 70
- Respiratory rate: 15

**General**

- No jaundice, no pallor, no oedema, no lymphadenopathy, no dehydration

**Head and Neck**

- No neck stiffness
- Vision and hearing intact
- Pupils equal and reactive to light
- No papilloedema
Chest

Chest clear

Cardiovascular

Normotensive
No murmurs, no added heart sounds

Abdomen

Not distended
Soft, no generalised tenderness
No organomegally
Bowel sounds present
No abnormalities detected

Neurological

Normal level of consciousness
Alert and co-operative
Continuous twitching of right hand- epilepsy partialis continua
Intermittent dystonic posturing of the left foot
Intermittent leg twitching
Sensation and power intact and normal globally
Tone and reflexes difficult to assess in right hand and left foot, all other areas normal
Gait, normal, able to walk unassisted
No seizures observed during initial examination

Dermatological

No skin rashes noted on examination

Two weeks following admission

The patient deteriorated rapidly over the following weeks from being independent to requiring assistance with walking and feeding. Her vision deteriorated and she developed dilated, sluggishly reactive pupils. There was no evidence of corneal or retinal involvement and no papilloedema.

She continued to have seizures which were difficult to control. Finally responding to a combination of valproate, levitiracetam and clonazepam.
## Investigations

<table>
<thead>
<tr>
<th>Test</th>
<th>Admission</th>
<th>1 week</th>
<th>2 weeks</th>
<th>3 week</th>
<th>Ref ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC</td>
<td>5.2</td>
<td></td>
<td></td>
<td>5.4</td>
<td>(4-12 x109/L)</td>
</tr>
<tr>
<td>HB</td>
<td>12.6</td>
<td></td>
<td></td>
<td>12.6</td>
<td>(12.1-15.2 g/L)</td>
</tr>
<tr>
<td>Platelets</td>
<td>201</td>
<td></td>
<td></td>
<td>218</td>
<td>(140-450 x109/L)</td>
</tr>
<tr>
<td>NA</td>
<td>138</td>
<td></td>
<td></td>
<td>137</td>
<td>(135-147 mmol/L)</td>
</tr>
<tr>
<td>K</td>
<td>4.5999999999999996</td>
<td></td>
<td>4.5999999999999996</td>
<td></td>
<td>(3.3-5.0 mmol/L)</td>
</tr>
<tr>
<td>CL</td>
<td>100</td>
<td></td>
<td></td>
<td>101</td>
<td>(99-103 µmol/L)</td>
</tr>
<tr>
<td>CO2</td>
<td>18</td>
<td></td>
<td></td>
<td>19</td>
<td>(18-29 mmol/L)</td>
</tr>
<tr>
<td>Urea</td>
<td>3</td>
<td></td>
<td></td>
<td>3</td>
<td>(2.5-6.4 mmol/L)</td>
</tr>
<tr>
<td>Creatinine</td>
<td>90</td>
<td></td>
<td></td>
<td>96</td>
<td>(62-115 mmol/L)</td>
</tr>
<tr>
<td>Glucose</td>
<td>4.2</td>
<td></td>
<td></td>
<td>4.8</td>
<td>(4-8 mmol/l)</td>
</tr>
<tr>
<td>CD4+</td>
<td>286</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral load</td>
<td>&lt;25 copies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF</td>
<td>Clear and colourless</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Appearance</td>
<td>Clear and colourless</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cells</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protein</td>
<td>0.4</td>
<td></td>
<td></td>
<td></td>
<td>0.15-0.45 g/L</td>
</tr>
<tr>
<td>Test</td>
<td>Admission</td>
<td>1 week</td>
<td>2 weeks</td>
<td>3 week</td>
<td>Ref ranges</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------</td>
<td>--------</td>
<td>---------</td>
<td>--------</td>
<td>-------------</td>
</tr>
<tr>
<td>Glucose</td>
<td>2.5</td>
<td></td>
<td></td>
<td></td>
<td>2.4 to 4.4 mmol/l</td>
</tr>
<tr>
<td>Neurosyphilis ag</td>
<td>neg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cryptococcal ag</td>
<td>neg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TB</td>
<td>neg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Culture</td>
<td>neg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV viral load</td>
<td>undetectable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCR - CSF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herpes Simplex virus 1 and 2</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
</tr>
<tr>
<td>CMV</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
</tr>
<tr>
<td>JC virus</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
</tr>
<tr>
<td>Epstein Barr</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
</tr>
<tr>
<td>Herpes virus 6</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
</tr>
<tr>
<td>Toxoplasmosis</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
</tr>
<tr>
<td>Fungi</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
</tr>
<tr>
<td>Enteroviruses</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
</tr>
<tr>
<td>Measles</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
<td>neg</td>
</tr>
<tr>
<td>Measles Serology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum IgG</td>
<td>Positive</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF IgG</td>
<td>neg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCR –brain biopsy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test</td>
<td>Admission</td>
<td>1 week</td>
<td>2 weeks</td>
<td>3 week</td>
<td>Ref ranges</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
<td>--------</td>
<td>---------</td>
<td>--------</td>
<td>------------</td>
</tr>
<tr>
<td>Measles</td>
<td></td>
<td></td>
<td></td>
<td>positive</td>
<td></td>
</tr>
</tbody>
</table>

**Electroencephalogram (EEG)**

Showed left periodic lateralised epileptiform discharges (PLEDs).

**CT Brain**

No abnormalities

**MRI**

Subtle non-enhancing left frontal cortical hyperintensity on the TR sequences of the initial MRI seen on week 3 of admission.

A repeat brain MRI showed contiguous spread of the left frontal lesion and additional multifocal T2-hyperintensities, but again limited to the cortical ribbon.

**Brain Biopsy**

Showed non-necrotising encephalitis with eosinophilic inclusions, suggestive of viral aetiology.

Measles PCR on brain tissue was positive.

**Discussion**

**Introduction**

Measles virus typically causes an acute disease characterized by fever, coughing, coryza, photophobia, nausea, and a macular red rash over most of the body. In rare instances measles virus may infect the central nervous system (CNS) as acute viral encephalitis, or result after 2 – 4 weeks in a post-infectious immune-mediated inflammatory disorder or acute disseminated encephalomyelitis (ADEM). In addition there are 2 rare and latent CNS complications which result from a preceding measles infection, namely, subacute sclerosing panencephalitis (SSPE) caused by years of viral persistence in a seemingly immunocompetent host, and subacute measles encephalitis (SME) which occurs in an immunocompromised host. Unlike SSPE, SME manifests sooner becoming apparent 1 – 7 months after the acute measles infection. These patients usually present with seizures, often epilepsy partialis continua and an altered mental status. The condition carries a mortality rate of 85% and survivors often have significant psychomotor retardation.
This discussion looks at this rare complication of measles infection, the neurological complications that develop and the immunological processes involved.

**Background**

**The measles virus infection cycle**

Measles virus is transmitted between humans by aerosal inhalation or contact with respiratory secretions. The main target cells are immune cells such as T and B cells, macrophages and dendritic cells that express CD150 (or signalling lymphocyte activation molecule [SLAM]) which serves as an entry receptor for measles. CD46 expressed on most cells can also be used by some wild-type strains but mostly by vaccine strains. Measles virus infects epithelial cells using nectin-4 as a receptor. It is also able to infect endothelial cells and neurons, but the entry receptors are unknown. It is thought that the first cells infected in the lungs are alveolar macrophages and dendritic cells that transport virus to regional lymph nodes where T and B cells become infected. Dissemination to other sites such as the spleen, lymphatic tissue, liver, thymus, skin and lungs follows. Measles virus is highly cytolytic. In peripheral tissues, adjacent infected cells may fuse together forming giant cells, or syncitia. This process occurs through the action of the viral fusion protein which is expressed on the surface of infected cells. The characteristic skin rash is immune-mediated due to infection of dermal capillary endothelial cells and immune complex formation. Infection of lung epithelial cells which occurs late during the infection cycle mediates transmission to other hosts.

Measles virus can also penetrate the brain, but is usually controlled by the immune system.

**How does measles virus enter the brain parenchyma?**

There are three potential routes of entry of measles virus into the brain:

1. The virus is able to infect neurons therefore it has been proposed that access to the brain via the olfactory bulb may occur.
2. Alternatively, the virus can replicate in capillary endothelial cells and thus may infect brain capillaries and release viral particles directly into the brain parenchyma.
3. Infection of monocytes in peripheral blood may allow transport of virus directly across the blood-brain barrier since monocytes transmigrate into the brain and differentiate into perivascular macrophages or microglial cells.

The following three graphics explain each of these routes in more detail:
1. Trans-synaptic migration through the olfactory bulb

Since measles virus can infect and spread through neurons it is possible that the virus may access the brain parenchyma by trans-synaptic migration through nerves in the olfactory bulb. Although a unique receptor on neurons remains to be identified, it may be possible for measles virus to penetrate olfactory neurons located in the nasal epithelium. Following penetration of a neuron, measles virus can migrate along a nerve bundle via cell-to-cell spread and ultimately enter the brain parenchyma. This is thought to be mediated by microfusion events between the axon and dendrites of adjacent neurons involving viral fusion proteins (F protein) and membrane proteins expressed by neurons (neurokinin-1).

2. Transmigration of monocytes across the blood-brain barrier

Bone-marrow derived monocytes are recruited to the brain where they mature into resident tissue macrophages (perivascular macrophages) or specialised brain macrophages (microglial cells). It is possible that measles virus can infect peripheral blood monocytes through the CD150 receptor. Some of these infected cells may enter the brain via the post-capillary venules (diapedesis) and thereby transport measles virus across the blood-brain-barrier. It is unlikely that virus particles can directly penetrate the brain because of the blood-brain barrier. Tight-junctions between capillary endothelial cells and the presence of a basement membrane prevents diffusion of large molecules into the brain.

3. Measles virus replication in brain capillary endothelial cells

Although the receptor remains to be identified, measles virus can replicate in endothelial cells lining blood vessels. It is therefore possible that replication of measles virus in endothelial cells of brain
Capillaries may allow infectious virus particles to bud directly into the brain parenchyma.

**Once dissemination to brain tissue has occurred**

Irrespective of the route of dissemination to the brain, once measles virus has penetrated the brain the target cells include perivascular macrophages, microglial cells and neurons. Importantly infection of neurons does not result in budding of virus particles from the cell membrane but instead viral spread occurs between neurons in a cell-to-cell manner with no induction of cytolysis.

**How the brain tissue controls infection**

**Non-cytolytic control of measles virus replication in neurons**

Mouse models of measles virus infection of the brain have shown that immune control of infected neurons is dependent on IL-12, CD4+ helper T cells and IFN-g. Infected neurons secrete chemokines (CCL5 and CXCL10) that attract T cells and antigen presenting cells (microglial cells and macrophages). Activated antigen presenting cells secrete IL-12 that promotes the differentiation of Th1 CD4+ helper T cells that secrete IFN-g and IL-2. Neurons express receptors for IFN-g that induces innate anti-viral responses. Although neurons do not express HLA class I receptors, as part of the immune privilege mechanisms in the brain that prevent CD8+ cytotoxic T cell attack, it has been shown that IFN-g stimulation can induce expression of HLA class I receptors on neurons. However, in the mouse model of measles virus infection of the brain, CD8+ cytotoxic T cells did not lyse infected neurons possibly due to additional immune privilege protective mechanisms in the brain.[link to immune privilege brain section]. Usually measles virus infection of the brain is controlled, but sometimes severe encephalitis occurs where neurons are damaged by excessive activation of immune cells and pro-inflammatory cytokine production.

**Immunosuppression during measles virus infection**

Acute infection with measles virus is associated with a robust Th1 cell-mediated immune response which resolves infection in the periphery. However during acute infection and for a number of weeks following clearance of measles virus, individuals have increased susceptibility to secondary infections. This is partially due to lymphopenia that occurs during acute infection, however cell numbers recover quickly. A switch from Th1 cell-mediated responses to Th2 has been proposed as the reason for longer lasting immunosuppression. This is possibly due to a lack of secretion of IL-12 by antigen presenting cells and an increase in IL-4 and TGF-b production. Also infected antigen presenting cells do not produce IL-12. A corresponding increase in IL-10 secretion by Th2 CD4+ T cells and regulatory T cells suppresses Th1 immune responses and may predispose individuals to other infections.

**How does the measles virus evade the immune system to result in SME?**

**Immune evasion of measles virus by cell-to-cell spread in neurons**
It has been shown that measles virus can spread between neurons in a cell-to-cell manner, but this process occurs very slowly. Initial penetration of neurons may still depend on a specific receptor which remains to be identified. However, after infection of a neuron, virus can then spread to adjacent neurons at the synapse from the dendrite to the axon (retrograde). The transport of virus from infected neurons to adjacent uninfected neurons is thought to be mediated by microfusion events at the cell membrane where viral F proteins bind neurokinin-1 receptors expressed on neurons that facilitate membrane fusion. Virus ribonuclear complexes accumulate at the cell membrane and can pass through to the adjacent cell. In neurons, there is incomplete assembly of infectious virus particles at the membrane. Budding of virus particles does not take place. Only the ribonuclear protein complexes are replicated and move from cell to cell. In particular the measles matrix, fusion and haemaglutinin proteins are poorly expressed. These proteins are major targets of the specific immune response during systemic infection. In this way the virus evades the immune response and persistent infection of the brain is established.

SME is a difficult diagnosis to confirm as was seen in this patient. Although in this case we were aware of the patient’s previous diagnosis of measles, the typical measles rash may be subtle or absent in an immunocompromised patient. The CSF examination is typically normal, and specific measles testing using antibodies and more sensitive PCR may be negative. As explained absence of measles virus RNA in the CSF is probably due to the intraneuronal location of the measles virus and, unlike non-neuronal cells, viral budding and shedding does not occur in the CNS. Furthermore, in the CNS, measles viral transmission occurs via trans-synaptic neuronal spread, which may explain the contiguous cortical spread on sequential MRI brain images. Therefore, in the absence of finding evidence of ongoing measles virus infection in the CSF in a patient where clinically there is a strong suspicion of previous measles infection, a definitive diagnosis would require brain biopsy.
Treatment

On admission the patient continued with ARVs, and multivitamins. Co-trimoxazole was stopped because CD4+ count was above 200 cells/mm3.

Seizures were treated with phenytoin, phenobarbitol and valproate but remained refractory to treatment. Eventually they were controlled with combination of valproate, levitiracetam and clonazepam.

A trial of Ribavirin, an anti-viral prodrug, which interferes with RNA metabolism was given, but failed to arrest progression of disease.

Download images for this case

Measles Virus

1 file(s) 2.38 MB
Download

Final Outcome

The patient deteriorated rapidly over the weeks following admission, from being independent to requiring assistance with walking and feeding. Her vision deteriorated and she developed dilated, sluggishly reactive pupils. There was no evidence of corneal or retinal involvement and no papilloedema. Despite commencement on oral ribavirin, her level of consciousness deteriorated. She is currently mute and unresponsive.

Download images for this case
Evaluation - Questions & answers

What is the diagnosis?
Subacute measles encephalitis (SME)

What is the condition?
Subacute measles encephalitis is a persistent measles virus infection of the brain which can develop in a severely immunocompromised host. One to seven months after the acute measles infection these patients will present with seizures, often epilepsy partialis continua and an altered mental status. The condition carries a mortality rate of 85% and survivors often have significant psychomotor retardation.

References

Link to abstract


Link to abstract


Link to abstract


Link to abstract

Download images for this case

Measles Virus
1 file(s) 2.38 MB
Download

Immunopaedia.org.za
Describe the immunopathogenesis of acute measles

Measles virus is transmitted between humans by aerosal inhalation or contact with respiratory secretions. The main target cells are immune cells such as T and B cells, macrophages and dendritic cells that express CD150 (or signalling lymphocyte activation molecule [SLAM]) which serves as an entry receptor. CD46 expressed on most cells can also be used by some wild-type strains but mainly by vaccine strains. It is thought that the first cells infected in the lungs are alveolar macrophages and dendritic cells that transport virus to regional lymph nodes where T and B cells become infected. The virus then disseminates to other sites including the skin. Measles virus can also penetrate the brain, but is usually controlled by the immune system.

How does the virus disseminate to the brain?

Three potential routes of entry have been proposed. The first route proposed is via the olfactory bulb as this is neuronal tissue and it is known that the virus can infect neurons. The second possible route is via brain capillaries as the virus is known to replicate in capillary endothelial cells. The third proposed route is via infected monocytes which transport virus across the blood-brain-barrier into perivascular macrophages or microglial cells.

How does a normal functioning immune system control virus that has disseminated to the brain parenchyma?

Infected neurons secrete chemokines (CCL5 and CXCL10) which attracts T cells and antigen presenting cells (microglial cells and macrophages). Antigen presenting cells secrete IL-12 that promotes the differentiation of Th1 CD4+ helper T cells that secrete IFN-g and IL-2. Neurons express receptors for IFN-g that induces innate anti-viral responses. CD8+ cytolytic T cells do not kill infected neurons most likely due to immune privilege mechanisms operating in the brain.

How does the measles virus evade the immune system and cause SME?

After infection of a neuron, virus spreads to adjacent neurons in a very slow cell-to-cell manner. This occurs at the synapse from the dendrite to the axon i.e. opposite to the usual flow of signals. The transport of virus from infected neurons to adjacent uninfected neurons is thought to be mediated by microfusion events at the cell membrane where viral F proteins (fusion protein) binds neurokinin-1 receptors expressed on neurons that facilitate membrane fusion. Virus ribonuclear protein complexes accumulate at the cell membrane and in this way pass through to the adjacent cell. In the neurons, there is incomplete assembly of infectious virus particles at the membrane and budding of virus does not take place. This prevents antibody detection of free virus and promotes virus persistence in the brain due to immune evasion.
Measles Virus

1 file(s) 2.38 MB
Download

Multiple Choice Questions

Earn 1 HPCSA or 0.25 SACNASP CPD Points - Online Quiz

Download images for this case

Measles Virus

1 file(s) 2.38 MB
Download